Maze Therapeutics, Inc.
Public company- Headquarters
- SOUTH SAN FRANCISCO, California
- Industry
- Biotechnology
- Ticker
- MAZE
- CIK
- 0001842295
WARN notices since 2024
0
None on record
Workers affected since 2024
0
Across 0 notices
Executive changes, last 12 months
6
4 appointments, 2 departures
Last event
Aug 17, 2026
Executive appointmentClass III director appointed: Paula A. Johnson, M.D., M.P.H.
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| Class III directorPaula A. Johnson, M.D., M.P.H. | Aug 17, 2026 | Appointed |
| Class I directorSophie Kornowski, Pharm.D. | Aug 17, 2026 | Appointed |
| Class II directorNancy C. Andrews, M.D., Ph.D. | Aug 17, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- Vir Biotechnology, Inc.
Class III director appointed: Suzanne Topalian, M.D.
- AMGEN INC
director appointed: David W. Gibbs
- Cardiff Oncology, Inc.
CMO appointed: Leila Alland
- Vaxart, Inc.
member of the Board appointed: Raquel C. Bono, M.D., M.B.A., FACS
No events of this type on record.
Show all eventsLast verified Nov 8, 2026